UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 OR 15 (d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) - November 1317, 2009

NUCRYST PHARMACEUTICALS CORP.

(Exact name of registrant as specified in its charter)


Alberta, Canada	000-51686	Not Applicable
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

NUCRYST Pharmaceuticals Corp.

101 College Road East

Princeton, New Jersey 08540

(Address of principal executive offices)

Registrant’s telephone number, including area code: (609) 228-8210

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 21.0201 ~~Results~~Entry ofinto ~~Operations~~a ~~and~~Material ~~Financial~~Definitive ~~Condition.~~Agreement

On November 1310, 2009, NUCRYST Pharmaceuticals Corp. (the “~~Company~~Corporation”) ~~issued~~and NUCRYST Pharmaceuticals Inc., a ~~press~~wholly ~~release~~owned ~~announcing~~subsidiary (the “Subsidiary” and collectively with the Corporation, “NUCRYST”) entered into a definitive agreement with subsidiaries of Smith & Nephew plc (LSE: SN; NYSE: SNN) for the sale to Smith & Nephew of substantially all of the NUCRYST’s operations and assets including all rights to its ~~financial~~proprietary ~~results~~nanocrystalline silver technology for cash consideration of U.S.$21 million plus the ~~quarter~~value ~~ended~~of ~~September~~working 30capital, ~~2009~~subject to certain adjustments (the “Sale Transaction”). The ~~press~~closing ~~release~~of isthe ~~attached~~Sale ~~hereto~~Transaction asis ~~Exhibit~~subject ~~99.1~~to ~~and~~customary isconditions ~~incorporated~~including, ~~herein~~without limitation, approval, by ~~reference~~special resolution at a duly convened meeting of the Corporation’s shareholders, of the sale of all or substantially all of the Corporation’s assets.

The ~~information~~Corporation inalso ~~this~~entered ~~Current~~into ~~Report~~an amalgamation agreement on ~~Form~~November ~~8-K~~10, ~~including~~2009 with The Westaim Corporation (“Westaim”) pursuant to which the ~~exhibit~~Corporation ~~attached~~will ~~hereto,~~amalgamate iswith ~~being~~a ~~furnished~~newly formed subsidiary of Westaim pursuant to the ~~United~~provisions ~~States~~of ~~Securities~~Section ~~and~~181 ~~Exchange~~of ~~Commission (~~the ~~“SEC”~~Business Corporations Act (Alberta) and ~~shall~~continue ~~not~~as beone ~~deemed~~corporation referred to beherein as Amalco (the “~~filed~~Amalgamation”). The ~~for~~shareholders ~~any~~of ~~purpose~~the Corporation, ~~nor~~other ~~shall~~than ~~such~~Westaim, ~~information~~will orreceive ~~such~~one ~~exhibit~~redeemable bepreferred ~~deemed~~share in the capital of ~~incorporated~~Amalco byfor ~~reference in~~each ~~any~~common ~~filing~~share ~~with~~of the ~~SEC~~Corporation ~~made~~held byand ~~the~~each ~~Company~~redeemable ~~under~~preferred share will be redeemed for U.S.$1.77 in cash upon the ~~Securities~~completion ~~Exchange~~of ~~Act~~the Amalgamation. Completion of ~~1934~~the Amalgamation is subject to certain conditions including, without orlimitation, closing of the ~~Securities~~Sale ~~Act~~Transaction ofand ~~1933~~the approval, ~~whether~~by ~~made~~a ~~before~~special orresolution ~~after~~at a duly convened meeting of the ~~date~~Corporation’s ~~hereof~~shareholders, ~~regardless~~ of ~~any~~the ~~general~~amalgamation ~~incorporation~~agreement ~~language~~described inabove ~~such~~and ~~filing~~the transactions contemplated thereby, ~~unless~~including ~~expressly~~the ~~set~~Amalgamation. Following ~~forth~~the bycompletion ~~specific~~of ~~reference~~the Amalgamation, the Corporation intends to ~~this~~delist ~~filing~~from the TSX and NASDAQ stock exchanges.

A copy of the press release announcing the Sale Transaction and Amalgamation dated November 10, 2009 is attached to this Current Report on Form 8-K as Exhibits 99.1 and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

Exhibit
Number		Description
99.1		Press Release, dated November 13, 2009, titled “NUCRYST announces 2009 third quarter financial results.”

Exhibit

Number

Description

99.1	Press Release, dated November 10, 2009, entitled “NUCRYST Announces Agreement to Sell Acticoat Business and Proposes Amalgamation with Westaim.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Nucryst Pharmaceuticals Corp.
	By:	/s/ Carol L. Amelio
		Carol L. Amelio
		Vice President, General Counsel and Corporate Secretary
Dated: November 13, 2009
Dated: November 17, 2009

EXHIBIT INDEX

Exhibit
Number		Description

99.1		Press Release, dated November 10, 2009, entitled “NUCRYST Announces Agreement to Sell Acticoat Business and Proposes Amalgamation with Westaim.”

Filing Compare · NUCRYST Pharmaceuticals Corp.